BIVI (BioVie) Moat Score: 3/10 (As of Jul. 04, 2026)


BIVI BioVie Inc BIVI
34 GF Score
Price $1.96
! 1 Warning Sign
View Full Analysis

What is BioVie Moat Score?

BioVie BIVI -10.55% 34 Moat Score is 3 as of Jul. 04, 2026. GuruFocus rates BIVI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,399 Biotechnology companies, BioVie ranks better than 75.48% on this metric.

BioVie has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

BioVie has No Moat: BioVie Inc operates in a competitive biotech industry with limited market share and no significant intellectual property or brand strength. The company's competitive position is weak, with minimal barriers to entry for competitors.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioVie might have No Moat - Very weak/transient advantages.

BioVie  (NAS:BIVI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioVie Moat Score Related Terms

BIVI vs CYCN, LNAI, CTXR: Moat Score Comparison

For the Biotechnology subindustry, BioVie's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Moat Score distribution charts can be found below:

* The bar in red indicates where BioVie's Moat Score falls into.


BIVI
34GF Score
BioVie Inc BIVI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
BioVie (BIVI) has a Moat Score of 3 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioVie ranks #343 out of 1399 companies in the Biotechnology industry, placing it in the top 24.5%.
Is BioVie's Moat Score too high?
BioVie's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. BioVie's value of 3 is 50% above this industry median. Based on the distribution chart, BioVie ranks #343 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioVie has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioVie's Moat Score compare to CYCN and LNAI?
According to the Biotechnology industry distribution chart, BioVie ranks #343 out of 1399 companies for Moat Score. This places BioVie in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. BioVie's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVie's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVie's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVie stock overvalued right now?
BioVie (BIVI) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. BioVie's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioVie (BIVI), the current Moat Score is 3 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVie Business Description

Address 680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
34GF Score

Get the complete analysis for BIVI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.96
Price